Brokerages Expect Erytech Pharma SA (NASDAQ:ERYP) to Announce -$0.80 Earnings Per Share

Share on StockTwits

Brokerages predict that Erytech Pharma SA (NASDAQ:ERYP) will post earnings of ($0.80) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Erytech Pharma’s earnings. The firm is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Erytech Pharma will report full-year earnings of ($2.82) per share for the current year. For the next fiscal year, analysts expect that the firm will report earnings of ($2.71) per share. Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Erytech Pharma.

Several brokerages have commented on ERYP. Zacks Investment Research upgraded shares of Erytech Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, July 10th. ValuEngine upgraded shares of Erytech Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 15th.

NASDAQ ERYP traded down $0.30 during trading on Friday, hitting $5.22. The company had a trading volume of 2,200 shares, compared to its average volume of 370. The company has a current ratio of 7.26, a quick ratio of 7.19 and a debt-to-equity ratio of 0.01. Erytech Pharma has a one year low of $5.20 and a one year high of $10.71. The company has a market cap of $93.65 million, a price-to-earnings ratio of 2.14 and a beta of 1.49. The company’s fifty day moving average is $6.16 and its 200-day moving average is $7.34.

Erytech Pharma Company Profile

ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.

See Also: Technical Analysis of Stocks and What It Means

Get a free copy of the Zacks research report on Erytech Pharma (ERYP)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Erytech Pharma (NASDAQ:ERYP)

Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with's FREE daily email newsletter.